Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.…
Treace Medical Concepts Inc (TMCI) Q3 2026 Earnings Call Highlights: Revenue Slips 4% but ...
Treace Medical Concepts (NASDAQ: TMCI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 450 employees.
The shares were at 4.310 USD on 20 November 2026, down 30.8% over 52 weeks. Its 52-week range is 1.170 USD to 5.430 USD: the price is 20.6% below the high and 268.4% above the low.
Its market capitalisation is 282.56M USD.
Treace Medical Concepts reports return on equity of -67.6%, an operating margin of -24.4% and revenue down 3.9% year over year.
Its debt exceeds its cash by 35.05M USD, a debt-to-equity ratio of 0.82. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 6.167 USD is 43.1% above the current price. The next earnings report is expected on 26 February 2027.